Philadelphia University + Thomas Jefferson University


Highlighted Publications

Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5:e1227897. PMID 27853651, PMCID PMC5087292

This paper shows that CAR-T cells targeting GUCY2C treat metastatic colorectal cancer without cause toxicity in GUCY2C-expressing tissues. PDF: Magee-2016-OncoImmunology

Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014;44:1956-66. PMID 24771148, PMCID PMC4107120

This paper shows that GUCY2C-specific self-tolerance is mediated by selective CD4+ T-cell tolerance which can be exploited to improve vaccine efficacy without impacting vaccine safety.  PDF: Snook-2014-Eur J Immunol

Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537-44. PMID 19351847, PMCID PMC2707278

This paper shows that GUCY2C vaccination safely induces antitumor immunity without autoimmunity.  PDF: Snook-2009-Cancer Res

Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950-61. PMID 18577748, PMCID PMC2749952

This paper demonstrates that GUCY2C is a potential cancer vaccine target.  PDF: Snook-2008-J Natl Cancer Inst

Recent Publications

Scopus Feed is currently unavailable.